{
    "2021-09-02": [
        [
            {
                "time": "",
                "original_text": "贝达药业港股上市审核状态标注“失效” 回应称“正常推进中”",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港股",
                        "上市",
                        "审核",
                        "失效",
                        "正常推进"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：拟推1555万股2021年限制性股票激励计划",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "限制性股票",
                        "激励计划",
                        "2021年"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）提名范建勋为非独立董事候选人",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "非独立董事",
                        "范建勋",
                        "提名"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）拟推出2021年限制性股票激励计划 授予价为41.34元/股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "限制性股票",
                        "激励计划",
                        "授予价",
                        "41.34元/股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：拟向激励对象468人授予限制性股票1555万股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "激励对象",
                        "限制性股票",
                        "1555万股",
                        "468人"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业FGFR4 抑制剂BPI-43487项目I期临床研究首例受试者入组",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "FGFR4抑制剂",
                        "BPI-43487",
                        "临床研究",
                        "首例受试者入组"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}